COPD, or chronic obstructive pulmonary disease, is a condition caused by damage to the airways or other parts of the lung that blocks airflow and makes it hard to breathe. COPD can cause coughing that produces large amounts of a slimy substance called mucus. It can also cause breathing problems, shortness of breath, chest tightness, and other symptoms. Because COPD is a progressive disease, its symptoms often develop slowly but worsen over time and can limit the ability to do routine activities. Serious COPD may prevent one from doing even basic activities such as walking, exercising, and taking care of oneself. According to the United States, the term COPD refers to two main conditions, such as Emphysema which develops when there is damage to the walls between many of the air sacs in the lungs. Normally, these sacs are elastic or stretchy. When breathing in, each air sac fills up with air, like a small balloon. When breathing out, the air sacs deflate, and air goes out. In emphysema, it is harder to move air out of the body. Chronic bronchitis is caused by repeated or constant irritation and inflammation in the lining of the airways. Lots of mucus forms in the airways, making it hard to breathe.
Most people who have COPD have a mixture of both emphysema and chronic bronchitis in different proportions, and the seriousness of the conditions varies from person to person. COPD is a major cause of disability and it is the sixth leading cause of death according to the Centers for Disease Control and Prevention. Cigarette smoking is a leading cause of COPD where majority of people who have COPD smoke or used to smoke. In the developing world, air pollution plays a much larger role. A rare genetic condition called alpha-1 antitrypsin deficiency can also cause disease. Although there is no cure for COPD, treatments, and lifestyle changes such as quitting smoking can help to feel better, stay more active, and slow the progress of the disease, also oxygen therapy, pulmonary rehabilitation, or medicine to treat complications.
Download Your Free PDF Sample: Unlock Key Market Insights @ https://cognizancemarketresearch.com/request/chronic-obstructive-pulmonary-disease-treatment-market/
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market – Competitive Landscape
On June 5, 2023, Pneumagen secured USD 8.7 million in investments to support the clinical development of its nasal spray, called Neumifil, for the prevention and treatment of virus-induced exacerbations in people with COPD. On May 16, 2023, Cambridge-based TidalSense raised USD 9.34 million to spread its AI-driven tech for respiratory conditions. February 27, 2023, VisionHealth secured USD 3.3 million to treat lung disease using its novel AI-powered device. On January 13, 2023, Aluna raised USD 15.3 million in series B funding to empower Asthma and COPD. On August 18, 2021, EpiEndo Pharmaceutical secured USD million series A funding to advance clinical development of its non-antibiotic Macrolide for the treatment of COPD.
Some of the Key Players in the Global Chronic Obstructive Pulmonary Disease Treatment Market Include –
- GlaxoSmithKline Plc
- AstraZeneca
- Boehringer Ingelheim Pharmaceutical
- Novartis International AG
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Sunovion Pharmaceuticals Inc.
- Cipla Limited
- Vertex Pharmaceuticals Incorporated
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market – Growth Drivers
The rising global prevalence of COPD, attributed to factors such as aging populations, tobacco use, and environmental pollution, is a key driver stimulating the market growth of chronic obstructive pulmonary treatment market growth. According to the National Center for Biotechnology Information (NCBI), the global prevalence of COPD ranges from 10.7% to 12.1%. Ongoing advancements in respiratory medicine, including inhalational therapies, biologics, and digital health solutions, drive innovation and contribute to the expansion of treatment options. Increased awareness campaigns and improved diagnostic techniques lead to early detection of COPD, fostering a higher demand for treatment and management strategies. Development and improvement of healthcare infrastructure globally enhance access to COPD treatments, especially in emerging markets, driving the COPD treatment market growth. The aging global population contributes to a higher incidence of COPD, driving the demand for effective options catering to the specific needs of elderly patients. Collaborations between pharmaceutical companies, research institutions, and healthcare providers stimulate research and development efforts, leading to the introduction of new and improved COPD treatments. Increasing acceptance of telehealth solutions facilitates remote monitoring and management of COPD, enhancing patient care and treatment adherence. The trend toward personalized medicine, tailored to individual patient profiles, encourages the development of targeted and more effective COPD treatments.
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market – Restraints
The cost of COPD medications and treatments can be a significant barrier, limiting access to effective therapies, particularly in regions with economic challenges. According to the National Center for Biotechnology Information (NCBI), the annual total COPD-related cost per patient is USD 4,147 Insufficient awareness about COPD symptoms and treatment options among both healthcare professionals and the general population hinders early detection and timely intervention. Difficulty in accurately diagnosing COPD, especially in its early stages, poses a restraint, leading to delayed treatment initiation and potentially poorer outcomes. Variations in healthcare infrastructure and accessibility across regions contribute to disparities in COPD treatment, impacting the quality of care in certain areas. Adverse effects associated with some COPD medications may lead to reduced patient compliance and reluctance to continue prescribed treatments. Resistance from healthcare systems and professionals to apt new treatment paradigms, such as personalized medicine or advanced inhalation therapies, can impede progress. Continued exposure to environmental pollutants and occupational hazards in certain regions exacerbates COPD, making it challenging to manage without addressing root causes. Increased availability of generic alternatives for COPD medications may lead to pricing pressures and reduced profit margins for pharmaceutical companies, potentially limiting research and development efforts.
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market – Opportunities
Opportunities arise from innovations in inhalation therapies, biologics, and digital health solutions for COPD management, enhancing treatment efficacy. Untapped potential in developing regions presents opportunities for COPD treatment market expansion as awareness of COPD grows, and healthcare infrastructure improves. Advancements in genomics and personalized medicine open avenues for tailoring COPD treatments to individual patient profiles, improving overall outcomes. Increasing acceptance of telemedicine provides opportunities for remote monitoring, enhancing patient compliance, and expanding access to COPD care globally. Collaboration with governments on awareness campaigns, subsidies, and regulatory support can create opportunities for market growth and improved patient outcomes.
Download Free PDF: Sample Our Market Research @ https://cognizancemarketresearch.com/request/chronic-obstructive-pulmonary-disease-treatment-market/
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market – Geographical Insight
The market for global chronic obstructive pulmonary disease treatment is segmented into regions such as North America, Latin America, Europe, Asia-Pacific, the Middle East & Africa. North America is the largest market for global chronic obstructive pulmonary disease treatment due to the high prevalence of COPD, particularly in the aging population. Robust healthcare infrastructure and availability of advanced treatments. Europe significant COPD burden, especially in countries with historically high smoking rates. Access to a variety of treatment options, but variations exist between Eastern and Western Europe. In the Asia-Pacific market region increasing COPD cases due to rising tobacco use and urbanization. With varied healthcare access, some regions may face challenges in treatment availability.
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market – Key Development
- On November 23, 2023, Lupin launched Vilfuro-G, the world’s first triple combo drug for COPD management in India.
- On November 13, 2023, Viatris and Theravance reported positive phase III COPD trial results.
- On August 23, 2023, the nationwide regulated AI technology N-Tidal device was launched for COPD diagnosis and management.
- On February 9, 2023, The European Federation of Allergies and Airways Disease launched a prize to welcome applications from innovators whose digital products improve the lives and health of asthma and COPD patients in Europe.
- On November 30, 2022, Pulmonx received Japanese MHLW approval for Zephyr Endobronchial Valve for the treatment of severe COPD.